We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $214M Turnover 33.33%
1-Year Est. Return 185.33%
This Fund
S&P 500
This Quarter Est. Return
+47.89%
1 Year Est. Return
+185.33%
3 Year Est. Return
+327.48%
5 Year Est. Return
+458.62%
10 Year Est. Return
+1,549.55%
AUM
$214M
AUM Growth
+$38.2M
Cap. Flow
-$12.5M
Cap. Flow %
-5.84%
Top 10 Hldgs %
59.94%
Holding
87
New
14
Increased
17
Reduced
22
Closed
15
Avg Time Held
2.3 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
2 years

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$3.66M
2
VIR icon
Vir Biotechnology
VIR
+$2.09M
3
ABVX icon
Abivax
ABVX
+$1.92M
4
HALO icon
Halozyme
HALO
+$1.58M
5
BIOA icon
BioAge Labs
BIOA
+$1.25M

Top Sells

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$4.04M
2
CMPS icon
Compass Pathways
CMPS
+$3.5M
3
GPCR icon
Structure Therapeutics
GPCR
+$3.36M
4
OCUL icon
Ocular Therapeutix
OCUL
+$2.71M
5
NVCR icon
NovoCure
NVCR
+$2.21M

Sector Composition

Rank Sector Weight
1 Healthcare 63.39%
2 Technology 32.27%
3 Energy 3.51%
4 Materials 0.53%
5 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KLAC icon
1
KLA
KLAC
$224B
$53.8M 25.18%
178,471
-20,359
-10% -$4.04M
2025 Q2
4 quarters
BMY icon
2
Bristol-Myers Squibb
BMY
$121B
$17.1M 8.01%
297,243
-9,025
-3% -$518K
2019 Q1
29 quarters
LRCX icon
3
Lam Research
LRCX
$347B
$15.2M 7.09%
35,000
-1,000
-3% -$304K
2025 Q4
2 quarters
NTLA icon
4
Intellia Therapeutics
NTLA
$1.64B
$6.78M 3.17%
385,900
-59,500
-13% -$833K
2025 Q2
4 quarters
SLDB icon
5
Solid Biosciences
SLDB
$612M
$6.66M 3.11%
666,196
+40,216
+6% +$305K
2025 Q1
5 quarters
BDSX icon
6
Biodesix
BDSX
$253M
$6.47M 3.02%
286,804
– –
2020 Q4
22 quarters
STOK icon
7
Stoke Therapeutics
STOK
$1.59B
$5.83M 2.73%
178,110
-31,890
-15% -$1.02M
2020 Q1
25 quarters
OVV icon
8
Ovintiv
OVV
$19.2B
$5.66M 2.65%
107,500
– –
2020 Q2
24 quarters
NKTR icon
9
Nektar Therapeutics
NKTR
$1.23B
$5.65M 2.64%
81,000
+50,000
+161% +$3.66M
2025 Q3
3 quarters
CORT icon
10
Corcept Therapeutics
CORT
$12.1B
$4.97M 2.33%
57,200
+10,000
+21% +$604K
2015 Q4
42 quarters
NBIX icon
11
Neurocrine Biosciences
NBIX
$13.8B
$4.58M 2.14%
27,190
– –
2015 Q3
43 quarters
PRTA icon
12
Prothena Corp
PRTA
$431M
$4.4M 2.06%
449,019
– –
2021 Q2
20 quarters
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$3.33B
$4.33M 2.02%
171,000
– –
2019 Q2
28 quarters
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.38B
$4.29M 2.01%
35,018
+18
+0.1% +$1.88K
2021 Q1
21 quarters
CMPX icon
15
Compass Therapeutics
CMPX
$153M
$3.67M 1.72%
1,675,000
+209,133
+14% +$617K
2025 Q3
3 quarters
RLMD icon
16
Relmada Therapeutics
RLMD
$334M
$2.82M 1.32%
408,100
-1,287
-0.3% -$8.99K
2026 Q1
1 quarter
ALKS icon
17
Alkermes
ALKS
$7.06B
$2.62M 1.23%
50,000
– –
2021 Q1
21 quarters
HALO icon
18
Halozyme
HALO
$14B
$2.6M 1.22%
33,251
+23,151
+229% +$1.58M
2022 Q4
14 quarters
CLDX icon
19
Celldex Therapeutics
CLDX
$2.24B
$2.6M 1.22%
69,900
-195
-0.3% -$6.3K
2026 Q1
1 quarter
CYTK icon
20
Cytokinetics
CYTK
$8.7B
$2.56M 1.2%
30,000
– –
2021 Q2
20 quarters
OLMA icon
21
Olema Pharmaceuticals
OLMA
$620M
$2.49M 1.16%
199,000
-20,000
-9% -$268K
2025 Q2
4 quarters
VERA icon
22
Vera Therapeutics
VERA
$2.05B
$2.48M 1.16%
57,758
+13,758
+31% +$513K
2025 Q4
2 quarters
UTHR icon
23
United Therapeutics
UTHR
$23.2B
$2.44M 1.14%
4,506
+6
+0.1% +$3.38K
2019 Q4
26 quarters
ZBIO icon
24
Zenas BioPharma
ZBIO
$1.72B
$2.38M 1.11%
93,601
+23,601
+34% +$469K
2026 Q1
1 quarter
QURE icon
25
uniQure
QURE
$1.52B
$2.34M 1.09%
50,697
-50,000
-50% -$1.31M
2024 Q3
7 quarters
1
2 3 4

Similar funds

EFIC
Eliot Finkel Investment Counsel Beverly Hills, California $214M AUM 62.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
RAM
Reflection Asset Management Isle Of Palms, South Carolina $214M AUM
TCM
Tassel Capital Management Matthews, North Carolina $214M AUM 16.99% 1-Year Est. Return
EFS
Econ Financial Services Harrisburg, Pennsylvania $214M AUM 10.53% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
FA
Fortis Advisors Wayne, Pennsylvania $214M AUM 41.3% 1-Year Est. Return
MSWM
Mader & Shannon Wealth Management Kansas City, Missouri $214M AUM 23.75% 1-Year Est. Return

Birchview Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Birchview Capital held 87 positions worth $214M, up 22% from $176M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Birchview Capital withdrew a net $12.5M in Q2 2026, closing 15 positions and reducing 22 holdings. Its most notable exit was NovoCure, an estimated $2.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 73% a quarter earlier, followed by Technology and Energy.

Against the trend, Birchview Capital opened a new position in Vir Biotechnology worth $2.24M.

  • Birchview Capital's largest Q2 2026 buy was Vir Biotechnology: 220,000 shares worth $2.24M.
  • Birchview Capital added most to Nektar Therapeutics in Q2 2026, an estimated $3.66M increase.
  • Birchview Capital's biggest Q2 2026 reduction was KLA, cutting an estimated $4.04M.
  • Birchview Capital fully exited NovoCure in Q2 2026, selling an estimated $2.21M.
  • Birchview Capital's ten largest holdings make up 60% of its $214M portfolio in Q2 2026.
  • Birchview Capital opened 14 new positions and closed 15 in Q2 2026.
  • Birchview Capital's portfolio value rose 22% quarter-over-quarter to $214M.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.